Statement on Glucagen Hypokit supply 2 August 2023 Novo Nordisk has notified the Therapeutic Goods Administration that the Glucagen Hypokit is currently in a shortage that will last until 30 September 2023. The Glucagen Hypokit is used to treat severe hypoglycaemia where a person is unconscious or unable to take oral hypo treatments. If a person has a severe hypo and you don’t have a Hypokit you need to call 000 immediately. Diabetes Australia is working with the diabetes sector and the TGA to ensure people at highest risk are prioritized access to available supply. The TGA have also activated Section 19A provisions and is arranging imports of Hypokits from other countries. If you have concerns please talk to someone from your diabetes healthcare team.
Media releases 30 April 2025 Melbourne to host International Diabetes Congress amid rising health crisis In a major win for Australia’s diabetes community, the International Diabetes Federation Western Pacific Region (IDF WPR) Congress 2026 will... Continue Reading
Media releases 28 April 2025 New nib foundation partnership to enhance diabetes care for people living with disability A groundbreaking new partnership between Diabetes Australia and nib foundation will improve the lives of people living with both diabetes... Continue Reading
News 3 April 2025 Public warning: Counterfeit Ozempic pens detected in Australia The Therapeutic Goods Administration (TGA) is urging the diabetes community to remain alert following the detection of counterfeit Ozempic-labelled injection... Continue Reading